{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-028323","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.362094+00:00","generated_at":"2026-05-26T02:30:45.760875+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvalent reports Q4 net loss $74.8M, cash $1.1B; pivotal data on track for 2025","bullets":["Net loss $74.8M (Q4 2024) and $260.8M (FY 2024); cash & equivalents $1.1B, expected to fund into 2028.","Pivotal data for zidesamtinib in TKI pre-treated ROS1+ NSCLC expected H1 2025; NDA submission mid-2025.","Pivotal data for neladalkib in TKI pre-treated ALK+ NSCLC expected year-end 2025; Phase 3 ALKAZAR initiating H1 2025.","Global Expanded Access Programs launched for zidesamtinib and neladalkib for eligible patients.","Appointed Grant Bogle, former Epizyme CEO, to Board of Directors in December 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-028323","json":"https://secwatch.observer/filing/0000950170-25-028323.json","markdown":"https://secwatch.observer/filing/0000950170-25-028323.md","text":"https://secwatch.observer/filing/0000950170-25-028323.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000095017025028323/0000950170-25-028323-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000095017025028323/nuvl-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:30:45.760875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}